Update on access to Zoladex treatment

BCNA is aware of AstraZeneca’s decision to discontinue the Zoladex (goserelin) 3.6mg implant in Australia from 1 November 2026. We understand this news may be unsettling for people currently using this treatment, and we want to acknowledge that we share your concerns.

At this stage, BCNA is seeking further information about the evidence supporting this change, particularly for people currently using the 3.6mg formulation. We have asked AstraZeneca to provide additional detail to help us better understand the rationale for the decision and its implications for the breast cancer community.

An alternative option, the Zoladex 10.8mg implant, will remain available. Work is currently underway to seek approval for its use in eligible people with breast cancer, and BCNA is also working to understand how the 10.8mg formulation would be accessed in the absence of a PBS listing, including any potential cost implications for consumers.

BCNA is consolidating feedback across the sector and working closely with AstraZeneca, key stakeholders and the clinical community to seek clarity, explore all available options, and minimise disruption for people affected by breast cancer.

If you are currently receiving Zoladex 3.6mg, supply will continue and we are working on a solution with all health professionals and government.  We will continue to keep patients and everyone involved up to date as soon as we have more information.

You can also contact our Helpline if you need support or would like to learn more about our advocacy on this issue.